samedan logo
 
 
 
spacer
home > ebr > spring 2004 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

Welcome to the Spring issue of European Biopharmaceutical Review, and with it what we all hope will be ongoing cause for optimism in the European biotechnology sector. Specifically, the successful flotation of Ark Therapeutics plc, raising £55 million on the London Stock Exchange at the beginning of March, is a very welcome development for all with an interest in European biotechnology and, most pertinently, to a number of other similar stage companies with products in development. Hopefully it will be the first of many for this group.

The prospect of a season of IPOs is likely to have significant impact elsewhere too - due diligence, for example will be increasingly in demand and rigorous, as illustrated by the articles in this issue from Bird & Bird and McGrigors. On a different level, the impact on deal-making between pharma and biotech, and indeed biotech and biotech, is likely to intensify as more and more product candidates start to come through the genomic/proteomic revolution, using more sophisticated biomarker and array-enabled proof-of-concept testing in vitro and in vivo. I am delighted to say that there is a real wealth of articles covering all of these aspects in this issue of EBR - from the deal-making reviews of DydoDelta Biosciences and PharmaVentures to the features on cell and array-based assays from ESBATech AG, VBC-Genomics, Evotec OAI and the like.

In particular, the impact of new technologies, new testing paradigms and new competition is well-reviewed in the areas of CNS, Oncology and HIV Clinical by Professor Gordon McVie, independent Oncology Advisor and Dr Phil Collis, VP Scientific Affairs at Inveresk Research. In addition, Dr Betsy Hughes-Formella of Bioskin GmbH and Dr Doris Heger-Mahn and colleagues from dinox GmbH lead interesting and provocative articles relating to conducting clinical trials in dermatology and reproductive medicine respectively, whilst Dr Francois Geelen expands on the real differences and practicalities of conducting clinical trials in different European countries (with a focus on Germany) under the new ICH framework.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Technology Consultant at London Technology Network
spacer
Dr Helen Abbott
spacer
spacer
spacer
Amy Curtis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus

1st September 2020 – Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and Hovione Technology, a pharmaceutical specialist in the development of innovative pulmonary device technology, today unveiled a collaboration supporting Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement